Findings

What do systematic reviews say?

8 questions · 8 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 1 · 12.5%Very low 0 · 0%Low 4 · 50%Moderate 0 · 0%High 0 · 0%

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Low molecular weight heparin and idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs vitamin K antagonist (VKA)

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.59]
3 studies · 561 participants
Low

Low molecular weight heparin vs no LMWH

All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.82 [0.53, 1.26]
5 studies · 1236 participants
Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
HR 0.94 [0.74, 1.2]
2 studies · 1243 participants
Low

Low molecular weight heparin vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs prostaglandin E1

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.99 [0.88, 1.12]
4 studies · 1712 participants
Low